6 also include the inﬂammatory cytokines, such as TNF, IL-1, IL-6, IL-8, and chemokines [40]. NF-kappaB is also involved in macrophage chemoattractant protein (MCP-1) gene expression as an intracellular signalling mechanism [41]. Vargas and colleagues [37] indicated that MCP-1 is one of the most prevalent cytokines in brain tissue from patients with autism. A better understanding of neuroinﬂammation in the pathogenesis of autism may have important clinical and therapeutic implications. So far, immune modulation and therapy, which have been applied to individuals with autism, are mainly limited to a number of case reports and no consensus treatment guidelines for immune therapies have been developed to physicians to use. Among the current studies of immune-targeted therapies, the collective data on steroid eﬀects on autism is the largest, mainly in the subgroup of patients with EEG abnormalities that go together with autistic regression [5]. Currently, the US National Institute of Health Clinical Center is recruiting participants to test the eﬀectiveness of minocycline in treating regressive autism through a blockade of NF-kappaB nuclear translocation. The anti- inﬂammatory antibiotic, minocycline, is a potent inhibitor of microglial activation, which reduces inﬂammation by blocking the nuclear translocation of the proinﬂammatory transcription factor, NF-kappaB. Also, there’s an evidence about minocycline beneﬁcial eﬀects in patients with FXS [42]. Calcineurin is also a common target of the immuno- suppressant drugs cyclophilin-cyclosporin A and FKBP- FK506 complexes [43]. Its inhibition has also been tested to achieve successful immunosuppression in patients after organ transplantation and in treating several other medical problems [44]. It is thought that autism results from an interaction between genetic and environmental factors with immuno- logical disorders as one of the potential mechanisms linking the two [45, 46]. Our results, with an emphasis on cal- cineurin and NF-kappaB, add further reasons for the need of more research into possible neuroimmune factors in the development of autism and as potential novel targets for treatments. 5. Conclusions In this study, it has been shown how the literature mining method can support medical experts on their way to discov- ering hidden relationships in data and a deeper understand- ing of complex disorders such as autism. The method has been proven as a very important tool, especially in the time of a vast amount of information at diﬀering levels of knowledge. Also, through the interaction of diﬀerent professionals the entire process of knowledge discovery can beneﬁt, by faster speed and guidance towards more meaningful solutions. An important feature of the two agents that emerged as potential links to autism in our study, calcineurin and NF-kappa, need to be further investigated to gain stronger evidence on their involvement in the development of the disorder. Autism Research and Treatment Abbreviations ICD-10 International Classiﬁcation of Diseases DSM-IV Diagnostic and Statistical Manual of Mental Disorders PRM Pervasive developmental disorders ASD Autism spectrum disorders MeSH Medical subject headings. Acknowledgment This paper was supported by the Slovenian Research Agency and by the European Commission under the 7th Frame- work Programme FP7-ICT-2007-C FET-Open, contract no. BISON-211898. References [1] Centers for Disease Control and Prevention (CDC), “Preva- lence of autism spectrum disorders—autism and devel- opmental disabilities monitoring network, United States, 2006. Autism and developmental disabilities monitoring net- work surveillance year 2006 principal investigators,” MMWR Surveillance Summaries, vol. 58, no. 10, pp. 1–20, Erratum in: MMWR Surveillance Summaries, vol. 58, no. 30, pp. 956. [2] S. Bent and R. L. Hendren, “Improving the prediction of response to therapy in autism,” Neurotherapeutics, vol. 7, no. 3, pp. 232–240, 2010. [3] M. Careaga, J. van de Water, and P. Ashwood, “Immune dysfunction in autism: a pathway to treatment,” Neurothera- peutics, vol. 7, no. 3, pp. 283–292, 2010. [4] R. J. Hagerman and R. L. Hendren, “Shifting the paradigm for autism treatments,” Neurotherapeutics, vol. 7, no. 3, pp. 230– 231, 2010. [5] M. G. Chez and N. Guido-Estrada, “Immune therapy in autism: historical experience and future directions with immunomodulatory therapy,” Neurotherapeutics, vol. 7, no. 3, pp. 293–301, 2010. [6] D. B. Campbell, J. S. Sutcliﬀe, P. J. Ebert et al., “A genetic variant that disrupts MET transcription is associated with autism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 45, pp. 16834–16839, 2006. [7] D. R. Swanson, “Medical literature as a potential source of new knowledge,” Bulletin of the Medical Library Association, vol. 78, no. 1, pp. 29–37, 1990. [8] M. Weeber, R. Vos, H. Klein, and T. W. De Jong-van den Berg, “Using concepts in literature-based discovery: simu- lating swanson’s Raynaud–ﬁsh oil and migraine–magnesium discoveries,” Journal of the American Society for Information Science and Technology, vol. 52, no. 7, pp. 548–557, 2001. [9] M. Weeber, R. Vos, H. Klein, L. T. W. De Jong-Van Den Berg, A. R. Aronson, and G. Molema, “Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide,” Journal of the American Medical Informatics Association, vol. 10, no. 3, pp. 252–259, 2003. [10] I. Petricˇ, T. Urbancˇicˇ, and B. Cestnik, “Discovering hidden knowledge from biomedical literature,” Informatica, vol. 31, no. 1, pp. 15–20, 2007. [11] T. Urbancˇicˇ, I. Petricˇ, B. Cestnik, and M. Macedoni-Luksˇicˇ, “Literature mining: towards better understanding of autism,”